Alliance Pharma (APH) - has today announced that Diclectin, a prescription treatment for nausea and vomiting of pregnancy has been given approvable status. This means that they should now be able to go ahead with marketing this in the UK & Europe as they had previously hoped. See their RNS for full details.
This should be good news ultimately and comes at a good time as to my mind the shares were starting to look a bit stretched in terms of their price and resultant valuation of 18 to 20x earnings and a sub 2% yield.
So it will be interesting to see how the share react to this and what, if any, updates we get to the effects of this on their earnings. I suspect this will only be beneficial for 2019 onwards as they have a December year end ans it is unlikely to be launched until the autumn and no doubt there will be up front costs associated with that.